Laxxon Medical

Laxxon Medical is a private, pre-revenue biotech firm developing a novel additive manufacturing platform (SPID®-Technology) for creating advanced oral dosage forms. Its business model focuses on three commercial solutions: patent extension for existing drugs, development of advanced patented generics, and new drug development, primarily leveraging the FDA's 505(b)(2) regulatory pathway. With a pipeline of 13 in-house assets and 4+ external projects, the company aims to capitalize on the impending patent cliff affecting over $100B in drug sales over the next decade.

SPID®-Technology (Screen Printed Innovative Drug Delivery), a proprietary 3D screen printing additive manufacturing platform for creating complex oral drug dosage forms with precise release profiles and combination capabilities.

Laxxon competes with other drug delivery technology companies and CDMOs offering life-cycle management services. Its unique differentiator is the focus on 3D screen printing for solid oral dosages. Direct competitors in 3D printed pharma include Aprecia Pharmaceuticals (ZipDose technology) and academic spin-offs, but the field remains nascent with significant white space.